Celik I, Duda D, Stinner B, Kimura K, Gajek H, Lorenz W
Institute of Theoretical Surgery, Philipps-University Marburg, Baldingerstrabetae, 35043 Marburg, Germany.
Inflamm Res. 2003 Oct;52(10):408-16. doi: 10.1007/s00011-003-1194-4.
The perioperative use of colloidal plasma substitutes is still under discussion. We therefore conducted a prospective randomised study with three commonly used plasma substitutes to examine their histamine releasing effects in 21 volunteers. MATERIAL OR SUBJETS: 21 male volunteers were enrolled in this prospective, randomised, controlled clinical study. Endpoints were the incidence of early and late histamine release and the time course of the release kinetics. Normovolemic hemodilution technique was used with hydroxyethyl starch (n = 6), human albumin (n = 6) and polygeline (n = 9). Measurement and observation period was 240 min after the start of the plasma substitute infusion. Heart rate, blood pressure, SaO(2), clinical symptoms/signs and plasma histamine were measured during the observation period.
The incidence of histamine release over the whole observation period in all three groups was 100%. Histamine release occurred frequently in all three groups until 30 min (50%-78%) and up to 240 min (late release reaction: 67%-83%) after the start of infusion. Surprisingly even hydroxyethyl starch, which is regarded as a generally safe and effective plasma substitute, caused high incidences of late histamine release (67%). Histamine release is a well known side effect of polygeline and - to a lesser extent - also of albumin, but was a novel finding for hydroxyethyl starch.
We demonstrated for the first time histamine releasing effects of hydroxyethyl starch over a long period of time after administration. This perioperatively and for intensive care possibly relevant finding should make clinicians aware of late side effects not yet connected with the clinical use of these colloidal plasma substitutes.
围手术期使用胶体血浆代用品仍存在争议。因此,我们对21名志愿者进行了一项前瞻性随机研究,使用三种常用的血浆代用品,以检测它们的组胺释放效应。材料或受试者:21名男性志愿者参与了这项前瞻性、随机、对照临床研究。观察终点为早期和晚期组胺释放的发生率以及释放动力学的时间过程。采用等容血液稀释技术,分别使用羟乙基淀粉(n = 6)、人白蛋白(n = 6)和聚明胶肽(n = 9)。在开始输注血浆代用品后240分钟为测量和观察期。在观察期内测量心率、血压、动脉血氧饱和度(SaO₂)、临床症状/体征以及血浆组胺水平。
在整个观察期内,所有三组的组胺释放发生率均为100%。在输注开始后的所有三组中,组胺释放频繁发生,直至30分钟(50%-78%),甚至在输注开始后240分钟(晚期释放反应:67%-83%)仍有发生。令人惊讶的是,即使是被认为一般安全有效的血浆代用品羟乙基淀粉,也导致了较高的晚期组胺释放发生率(67%)。组胺释放是聚明胶肽的一种众所周知的副作用,在较小程度上也是白蛋白的副作用,但对于羟乙基淀粉来说却是一个新发现。
我们首次证明了羟乙基淀粉在给药后很长一段时间内具有组胺释放效应。这一围手术期及重症监护可能相关的发现应使临床医生意识到这些胶体血浆代用品临床使用中尚未出现的晚期副作用。